A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2016
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary) ; Dexamethasone; Dexamethasone; Fludarabine; Mitoxantrone
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 19 Dec 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 18 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 18 Dec 2014 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, according to the ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History